EP0000968A1 - Pharmazeutisches Präparat mit anti-infektiöser, entzündungshemmender und anti-asthenischer Wirkung - Google Patents

Pharmazeutisches Präparat mit anti-infektiöser, entzündungshemmender und anti-asthenischer Wirkung Download PDF

Info

Publication number
EP0000968A1
EP0000968A1 EP78200130A EP78200130A EP0000968A1 EP 0000968 A1 EP0000968 A1 EP 0000968A1 EP 78200130 A EP78200130 A EP 78200130A EP 78200130 A EP78200130 A EP 78200130A EP 0000968 A1 EP0000968 A1 EP 0000968A1
Authority
EP
European Patent Office
Prior art keywords
gluconate
composition according
gold
copper
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78200130A
Other languages
English (en)
French (fr)
Other versions
EP0000968B1 (de
Inventor
Catherine Geneviève Suck
Liliane Lepeix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0000968A1 publication Critical patent/EP0000968A1/de
Application granted granted Critical
Publication of EP0000968B1 publication Critical patent/EP0000968B1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to new pharmaceutical compositions having an antiinfectious, antiinflammatory and antiasthenic action.
  • trace elements which are generally metals which are found in the natural state as well in the mineral kingdom as in the vegetable or animal kingdom.
  • Trace elements therefore intervene essentially, by reactivating them, on the patient's own organic defenses so that they give the organism the possibility of recovering its own balance on its own.
  • compositions based on gold and copper and silver compounds intended for the treatment of infectious conditions.
  • Silver has bactericidal properties, copper has anti-infectious properties and gold has anti-inflammatory properties.
  • compositions although particularly effective in acute cases, are not suitable for other types of conditions characterized for example by a general state of tiredness or by their chronicity. It is necessary in these cases to use an agent promoting oxidoreduction.
  • compositions in accordance with the present invention therefore aim to act on the lack of self-defense, physical fatigability and mental fatigue which precede or accompany chronic conditions, recurrent or repeated affections, convalescence or senescence.
  • gold plays a role in the anti-toxic, anti-inflammatory and anti-rheumatic reactions. Copper promotes the development of antibodies and boosts the activity of ascorbic acid which acts in particular on the functioning of the adrenals. For its part, manganese, playing a redox role, intervenes at the intermediate metabolism level and in particular in the synthesis of hemoglobin, in the establishment of immunity and therefore produces an antiasthenic effect.
  • composition is prescribed at the rate of 1/2 to 2 unit doses per day. No toxicity was noted during the last tests.
  • a 45-year-old man with osteoarthritis was administered 1 dose daily for 12 days; the treatment was particularly effective and we noted a restoration of the general balance with disappearance of the fatigue.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP78200130A 1977-08-11 1978-08-04 Pharmazeutisches Präparat mit anti-infektiöser, entzündungshemmender und anti-asthenischer Wirkung Expired EP0000968B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7724685 1977-08-11
FR7724685A FR2399842A1 (fr) 1977-08-11 1977-08-11 Nouvelle composition antiinfectieuse, antiinflammatoire et antiasthenique

Publications (2)

Publication Number Publication Date
EP0000968A1 true EP0000968A1 (de) 1979-03-07
EP0000968B1 EP0000968B1 (de) 1981-10-14

Family

ID=9194452

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78200130A Expired EP0000968B1 (de) 1977-08-11 1978-08-04 Pharmazeutisches Präparat mit anti-infektiöser, entzündungshemmender und anti-asthenischer Wirkung

Country Status (7)

Country Link
EP (1) EP0000968B1 (de)
JP (1) JPS5432637A (de)
CA (1) CA1108536A (de)
DE (1) DE2861161D1 (de)
ES (1) ES470802A1 (de)
FR (1) FR2399842A1 (de)
PT (1) PT68176A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058693A1 (de) * 2006-11-17 2008-05-22 Ada Cosmetic Gmbh Körper- oder schönheitspflegemittel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE674532A (de) * 1964-12-31 1966-04-15

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1579457A (de) * 1964-12-31 1969-08-29

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE674532A (de) * 1964-12-31 1966-04-15

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIDAL 1967, page 943, "Cuivre-or-argent oligosol", "Manganèse-cuivre-oligosol" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058693A1 (de) * 2006-11-17 2008-05-22 Ada Cosmetic Gmbh Körper- oder schönheitspflegemittel

Also Published As

Publication number Publication date
JPS5432637A (en) 1979-03-10
ES470802A1 (es) 1979-04-01
DE2861161D1 (en) 1981-12-24
FR2399842B1 (de) 1981-10-23
FR2399842A1 (fr) 1979-03-09
CA1108536A (fr) 1981-09-08
EP0000968B1 (de) 1981-10-14
PT68176A (fr) 1978-07-01

Similar Documents

Publication Publication Date Title
Guimarães et al. Potent anti‐inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo
JP2006519244A (ja) 糖尿病患者の治療におけるω−３−脂肪酸の使用
Bader The safety profile of De-Nol
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
RU2004121177A (ru) Применение прамипексола для лечения бокового амитрофического склероза
Malkinson et al. Hydroxychloroquine treatment of porphyria cutanea tarda
FR2415112A1 (fr) Nouveaux derives spirothienohydantoines et composition pharmaceutique les contenant
DE69333575D1 (de) Quinone-derivate zur verbesserung der zellulare bioenergie
EP0109873A1 (de) Therapeutische Zusammensetzung enthaltend DNA und Allantoin, die besonders für die Vernarbung von Wunden nützlich ist
WO1987004926A2 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
Huang et al. Induction of cyclooxygenase-2 mRNA and protein expression by epoxy resin and zinc oxide-eugenol based root canal sealers in human osteoblastic cells
Doly et al. Oxidative stress in diabetic retina
EP0000968B1 (de) Pharmazeutisches Präparat mit anti-infektiöser, entzündungshemmender und anti-asthenischer Wirkung
FR2434162A1 (fr) Nouveaux derives de 4-amino-2-piperidino-quinazoline, leur procede de production et medicament les contenant
RU2006128209A (ru) Фармацевтическая композиция для лечения псориаза, содержащая l-серин, l-изолейцин, фолиевую кислоту и микроэлементы
ATE178207T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
WO2003080062A1 (en) Composition comprising vitamin b9, vitamin b6, lipoic acid and plant extracts for treating circulatory disorders
Ulmansky et al. Response of pulpotomy wounds in normal human teeth to successively applied Ledermix and Calxyl
WO1998036744A1 (fr) Utilisation du milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
EP0152366A2 (de) Zusammensetzungen zur therapeutischen Verwendung mit Gehalt an Organo-Silizium-Verbindungen
EP3624822B1 (de) Aktive zusammensetzung enthaltend eine mischung von poly-lysine verbindungen, und verwendung zur behandlung und vorbeugung der entzündung nach schlaganfall
Birkmayer et al. Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution
Sollmann et al. Excretion of mercury after clinical intramuscular and intravenous injections
ATE465254T1 (de) Verbindung, zusammensetzung und verfahren zur behandlung von entzündlichen und entzündungs- verwandten erkrankungen
FR2675384A1 (fr) Complexes de l'acide polyadenylique avec l'acide polyuridylique.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE GB LU NL SE

REF Corresponds to:

Ref document number: 2861161

Country of ref document: DE

Date of ref document: 19811224

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 78200130.9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19970715

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19970721

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19970724

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19970728

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19970730

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970825

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19970831

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 980804 *SUCK CATHERINE GENEVIEVE;*LEPEIX LILIANE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980803

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980804

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980805

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19980803

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19980804

EUG Se: european patent has lapsed

Ref document number: 78200130.9

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT